Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences (REVB)
NASDAQ:REVB
REVB Stock Chart & Stats
$0.90
-$0.04(-6.62%)
At close: 4:00 PM EST
$0.90
-$0.04(-6.62%)
Day’s Range― - ―
52-Week Range$1.61 - $55.20
Previous CloseN/A
Volume326.26K
Average Volume (3M)740.56K
Market Cap
$2.98M
Enterprise Value-$10.24M
Total Cash (Recent Filing)$12.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 26, 2026EPS Estimate
-3.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.08
Shares Outstanding1,583,951
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.81
Price to Sales (P/S)0.00
P/FCF Ratio-0.21
Enterprise Value/Market Cap-3.44
Enterprise Value/Revenue-379.59
Enterprise Value/Gross Profit-759.17
Enterprise Value/Ebitda1.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers financial risk for a clinical-stage biotech. With no interest burden, the company retains flexibility to allocate capital to R&D and regulatory work, improving survivability through multi-phase clinical programs and reducing default risk.
Near-term Liquidity From Warrant InducementThe $7.3M raised via warrant inducement provides tangible runway to advance clinical plans and GMP activities. This non-revenue cash infusion reduces immediate financing pressure, allowing program milestones and regulatory interactions to proceed without an immediate dilutive public raise.
Clinical Progress And FDA EngagementCompleting Phase 1b and agreeing a regulatory pathway with the FDA are durable value drivers: they de-risk development, enable clearer development plans toward Phase 2/3, and increase the asset's strategic optionality for partnerships or licensing ahead of commercialization.
Bears Say
No Revenue And Persistent LossesLack of revenue and sustained net losses mean the business cannot self-fund development. Over the medium term this structural reliance on external capital increases execution risk, potential dilution, and puts pressure on management to secure financing before key milestones.
Significant Negative Cash Flow And BurnMaterial negative operating and free cash flow that is worsening creates a persistent funding gap. This structural cash burn necessitates repeated financing rounds, limiting strategic flexibility, increasing dilution over time, and elevating risk if capital markets tighten.
Warrant Overhang And Dilution RiskThe inducement deal issues new multi-year warrants and extends expirations, creating prolonged potential equity dilution and overhang. This structural cap table pressure can impair future financing terms, complicate valuation negotiations, and reduce per-share upside for existing holders.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $1.61 and its highest was $55.20 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $2.98M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is Mar 26, 2026 which is in 49 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on Nov 06, 2025. The company reported -$7.08 earnings per share for the quarter, missing the consensus estimate of -$5.34 by -$1.74.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Overvalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -3.66.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 1,583,951 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$7.08 in its last earnings report, missing expectations of -$5.34. Following the earnings report the stock price went down -2.921%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
40.92% Insiders
0.02% Mutual Funds
6.15% Other Institutional Investors
52.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---